Chad Landmon

1 month ago | jdsupra.com | Chad Landmon |Andrew Solomon

March 10, 2025 To embed, copy and paste the code into your website or blog: Late last year we reported on the United States Court of Appeals for the Federal Circuit decision holding that certain device patents should not have been listed in the FDA’s Orange Book since the claims of the patents in question did not recite the active drug substance.

Jan 23, 2025 | lifescienceleader.com | Chad Landmon |Andrew Solomon

Guest Column | January 23, 2025 By Chad Landmon and Andrew Solomon When a brand pharmaceutical company develops a new drug product, one of its early key considerations is whether it has any patents protecting the drug and if those patents should be listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

Jul 18, 2024 | jdsupra.com | Chad Landmon |Andrew Solomon

July 18, 2024 To embed, copy and paste the code into your website or blog: On September 23, 2023, the FTC issued a policy statement advising it would be putting market participants on notice that it intends to scrutinize improper Orange Book listings to determine whether such actions constitute unfair methods of competition in violation of the Sherman Act.1 On November 7, 2023, FTC made good on its promise by issuing Warning Letters to ten different manufacturers of seventeen different...

Jul 17, 2024 | natlawreview.com | Jason Feingertz |Zachary Roop |Mary Jane Wilmoth |Chad Landmon

Skip to main content July 17, 2024 Volume XIV, Number 199 Legal Analysis. Expertly Written. Quickly Found.

Jul 17, 2024 | natlawreview.com | Chad Landmon

On September 23, 2023, the FTC issued a policy statement advising it would be putting market participants on notice that it intends to scrutinize improper Orange Book listings to determine whether such actions constitute unfair methods of competition in violation of the Sherman Act.1 On November 7, 2023, FTC made good on its promise by issuing Warning Letters to ten different manufacturers of seventeen different brand-name asthma inhalers, epinephrine autoinjectors and other drug products...